Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
3979694 | Cancer Treatment Communications | 2014 | 4 Pages |
Abstract
We report a case of a 59-year-old woman with brain metastases from an EGFR mutated adenocarcinoma of the lung. She was initially treated with erlotinib and two times whole brain radiation therapy. After a second relapse within the CNS the therapy was switched to gefitinib and a partial remission of the brain metastases could be achieved. Our case demonstrates that patients can respond to a switch of the EGFR TKI also within the CNS despite heavy pre-treatment. The article reviews the literature regarding the efficacy of tyrosine kinase inhibitors in brain metastases from lung cancers.
Related Topics
Health Sciences
Medicine and Dentistry
Oncology
Authors
C. Leitner, R. von Moos, M. Mark, M. Früh, R. Cathomas,